Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4Thoracic 3Other hematologic neoplasm 2Gynecologic 2Genitourinary 2Breast 2Myeloid 1Head & Neck 1CNS 1

Conditions

Prostatic Neoplasms 2Lung Neoplasms 1

Interventions

Docetaxel 409pembrolizumab 331Prednisone 290enzalutamide 285Gemcitabine 274Radiotherapy 270Magnetic Resonance Spectroscopy 269Nivolumab 253Abiraterone Acetate 218Cisplatin 212Leuprolide 195Radiosurgery 192Sunitinib 188Carboplatin 161Androgen Antagonists 156bicalutamide 152Specimen Handling 149Goserelin 149Ipilimumab 131Paclitaxel 126acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 122apalutamide 118Cyclophosphamide 117Bevacizumab 116Sorafenib 114Everolimus 111abiraterone 108cabozantinib 105atezolizumab 105Biopsy 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Diagnosis × Genitourinary × Clear all
NCT07526545 2026-04-13

UPRISE

University of Michigan Rogel Cancer Center

Phase NA Not yet recruiting
800 enrolled
Genitourinary

Prostatic Neoplasms

NCT00581503 2022-10-20

Early Detection and Staging of Endobronchial Lung and Pleural Cancer, Airway Injury, and Prostate Cancer

University of California, Irvine

Withdrawn
GenitourinaryThoracic

Lung Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡